Clinical Trial Update: Efficacy and Safety of BiomatrixTM Stent and 5mg-Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating the efficacy and safety of the Biomatrix Stent with a 5 mg maintenance dose of prasugrel in patients with Acute Coronary Syn…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome

Drugs mentioned

• Biomatrix Stent
• PRASUGREL (prasugrel)

Snippet

Sponsor: Chonnam National University Hospital | Conditions: Cardiac Death, Hemorrhage | Phase 4 | Status: UNKNOWN